Disease Information

General Information of the Disease (ID: DIS00547)
Name
Ovarian cancer
ICD
ICD-11: 2C73
Resistance Map
Type(s) of Resistant Mechanism of This Disease
  MRAP: Metabolic Reprogramming via Altered Pathways
Drug Resistance Data Categorized by Drug
Approved Drug(s)
2 drug(s) in total
Click to Show/Hide the Full List of Drugs
Docetaxel
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
  Metabolic Reprogramming via Altered Pathways (MRAP) Click to Show/Hide
Key Molecule: Cystine/glutamate transporter (SLC7A11) [1]
Metabolic Type Redox metabolism
Resistant Disease Ovarian clear cell carcinoma [ICD-11: 2C73.00]
Resistant Drug Docetaxel
 Drug Info 
Molecule Alteration Expression
Up-regulation
 Molecule Info 
Differential expression of the molecule in resistant disease
Classification of Disease Ovarian cancer [ICD-11: 2C73]
The Specified Disease Ovarian cancer
The Studied Tissue Ovarian tissue
The Expression Level of Disease Section Compare with the Healthy Individual Tissue
p-value: 2.27E-01
Fold-change: 1.23E-01
Z-score: 1.31E+00
Experimental Note Revealed Based on the Cell Line Data
In Vitro Model Caov-3 cells Ovary Homo sapiens (Human) CVCL_0201
ES-2 cells Ovary Homo sapiens (Human) CVCL_3509
HAC-2 cells Ovary Homo sapiens (Human) CVCL_8354
RMG-1 cells Ascites Homo sapiens (Human) CVCL_1662
SKOV-3 cells Ovary Homo sapiens (Human) CVCL_0532
TOV21G cells Ovary Homo sapiens (Human) CVCL_3613
Experiment for
Molecule Alteration		 Western blot analysis
Experiment for
Drug Resistance		 IC50 assay
Mechanism Description This study demonstrated that combined treatment with paclitaxel (PTX) and the xCT inhibitor sulfasalazine (SAS) significantly enhanced cytotoxicity more than the individual drugs did in OCCC cells. Treatment with PTX and SAS induced apoptosis more effectively than did individual drug treatments in the cells with significant generation of ROS.
Sulfasalazine
Click to Show/Hide
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
  Metabolic Reprogramming via Altered Pathways (MRAP) Click to Show/Hide
Key Molecule: Cystine/glutamate transporter (SLC7A11) [1]
Metabolic Type Redox metabolism
Sensitive Disease Ovarian clear cell carcinoma [ICD-11: 2C73.00]
Sensitive Drug Sulfasalazine
 Drug Info 
Molecule Alteration Expression
Up-regulation
 Molecule Info 
Experimental Note Revealed Based on the Cell Line Data
In Vitro Model Caov-3 cells Ovary Homo sapiens (Human) CVCL_0201
ES-2 cells Ovary Homo sapiens (Human) CVCL_3509
HAC-2 cells Ovary Homo sapiens (Human) CVCL_8354
RMG-1 cells Ascites Homo sapiens (Human) CVCL_1662
SKOV-3 cells Ovary Homo sapiens (Human) CVCL_0532
TOV21G cells Ovary Homo sapiens (Human) CVCL_3613
Experiment for
Molecule Alteration		 Western blot analysis
Experiment for
Drug Resistance		 IC50 assay
Mechanism Description This study demonstrated that combined treatment with paclitaxel (PTX) and the xCT inhibitor sulfasalazine (SAS) significantly enhanced cytotoxicity more than the individual drugs did in OCCC cells. Treatment with PTX and SAS induced apoptosis more effectively than did individual drug treatments in the cells with significant generation of ROS.
References
Ref 1 Mechanism of Cell Death by Combined Treatment with an xCT Inhibitor and Paclitaxel: An Alternative Therapeutic Strategy for Patients with Ovarian Clear Cell Carcinoma. Int J Mol Sci. 2023 Jul 22;24(14):11781.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Yu.